CRESCENT BIOPHARMA, INC. — Director's Dealing 2017

Mar 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2017-03-09

Reporting Person: Koenig Scott (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-09	Stock Option (right to buy)	$6.59	A	22000	Acquired	2027-03-09	Common Stock (22000)	Direct

Footnotes

F1: This option grant was made pursuant to the issuer's non-employee director compensation policy. The shares underlying this option vest in three equal installments on March 9, 2018, 2019 and 2020, subject to the reporting person's continuous service with the issuer at each vesting date.